News summary

Insulin safeguards apoptotic fate of mesenchymal stem cells to sustain long-term therapeutic efficacy in type 2 diabetes

Source: Nature - Biotechnology • Published: 02 Nov 2026, 00:00

Summarized by Masters of Longevity from Nature - Biotechnology.

In diabetic mice, insulin with umbilical cord MSCs preserved prolonged metabolic benefits.

Insulin safeguards apoptotic fate of mesenchymal stem cells to sustain long-term therapeutic efficacy in type 2 diabetes
Key Takeaways
  • Combination therapy was more durable than UCMSC monotherapy.
  • Insulin promoted early MSC apoptosis and increased apoV production.
  • Insulin-primed apoVs alone produced prolonged metabolic benefits.
Read the full article at Nature - Biotechnology ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.